COVID-19 — Endothelial Axis and Coronary Artery Bypass Graft Patency: a Target for Therapeutic Intervention?

Gokce Topal¹, PhD; Andrzej Loesch², PhD; Michael R. Dashwood³, PhD

Abstract

It has been reported that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection induces endothelial inflammation, therefore facilitating the progression of endothelial and vascular dysfunction in coronavirus disease 2019 (COVID-19) patients. Coronary artery bypass grafting (CABG) involves mainly the use of the saphenous vein (SV) and internal mammary artery as graft material in the stenosed coronary arteries. Unfortunately, graft patency of the SV is low due to endothelial dysfunction and inflammation. We propose that SARS-CoV-2 might cause vascular inflammation, endothelial dysfunction, and thrombosis in coronary artery bypass graft vessels by binding angiotensin-converting enzyme 2 receptor. Therefore, in this Special Article, we consider the potential influence of COVID-19 on the patency rates of coronary artery bypass graft vessels, mainly with reference to the SV. Moreover, we discuss the technique of SV graft harvesting and the therapeutic potential of focusing on endothelial dysfunction, vascular inflammation, and thrombosis for protecting coronary artery bypass grafts in COVID-19 infected CABG patients.

Keywords: COVID-19. SARS Virus. Coronary Artery Bypass Graft Surgery. Saphenous Vein. Endothelial Dysfunction. Vascular Inflammation.

INTRODUCTION

There is increasing evidence demonstrating the impact of coronavirus disease 2019 (COVID-19) on cardiovascular function in patients with pre-existing cardiovascular disease¹². Recently, Mehra et al.⁴ demonstrated and confirmed previous reports showing that an underlying cardiovascular disease (coronary artery disease [CAD], heart failure, and cardiac arrhythmias) is associated with an increased risk of in-hospital death among patients with COVID-19. Furthermore, evidence of direct viral infection of endothelial cells and diffuse endothelial inflammation by COVID-19 has been demonstrated, suggesting that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection...
facilitates endothelial injury. An example of such pathological changes showing accumulation of inflammatory cells, resulting in endothelial dysfunction, is presented in a histological study of vascular tissue of postmortem human kidney, bowel, and lung in COVID-19 patients\textsuperscript{[9,10,12]} (Figure 1). Moreover, the recent letter of Qanadli et al.\textsuperscript{[13]} describes the vascular appearance in COVID-19 patients, as “vascular thickening”, an observation confirmed more recently by Bai et al.\textsuperscript{[16]} Together, these findings suggest that there is an effect of COVID-19 on vascular function and, therefore, that this virus plays an important role in vascular dysfunction and inflammation in COVID-19 patients. In fact, due to the complex cardiovascular features of COVID-19 patients, major cardiology organizations, including the European Society of Cardiology and American College of Cardiology, have issued bulletins for the diagnosis, management, and clinical guidance of cardiovascular disease during the COVID-19 pandemic\textsuperscript{[7,8,9]}.

Angiotensin-converting enzyme 2 (ACE2), which presents high homology with angiotensin converting enzyme (ACE), is a key enzyme in the renin-angiotensin-aldosterone system (RAAS). Moreover, ACE2 is also a critical receptor for SARS-CoV-2 infections\textsuperscript{[9,10,13,14]}. These findings indicate that ACE2 might be crucial for the human infection of SARS-CoV-2 and for the progression and prognosis of COVID-19. Organs expressing a high level of ACE2 are potential targets of SARS-CoV-2 infection. The subsequent tissue damage and inflammation cause severe complications that may worsen the clinical outcome\textsuperscript{[9,10,13,14]}. Interestingly, Donoghue et al.\textsuperscript{[11,12]} demonstrated that ACE2 is expressed in the endothelium of most human intramyocardial vessels including capillaries, venules, medium-sized coronary arteries, and arterioles. In this study, the authors showed immunostaining of vascular smooth muscle cells and focal staining in the adventitia of some larger vessels. Furthermore, ACE2 expression of endothelial cells lining the lumen of the human saphenous vein (SV), commonly used as a coronary artery bypass graft, has been demonstrated as well as those endothelial cells of the adventitial vasa vasorum\textsuperscript{[11,12]}. However, while ACE2 immunoreactivity of the luminal endothelium was not observed in a separate study, it was clearly present in the medial layer of the internal mammary artery (IMA), the gold standard coronary artery bypass conduit\textsuperscript{[11,12,13]}. However, both studies were performed on small sample numbers and on patients receiving drug therapies that might influence the results.

Coronary artery bypass grafting (CABG) is performed on over one million patients a year in order to restore myocardial blood supply. CABG involves mainly the use of SV and IMA as graft material in the stenosed coronary arteries. SV is the most widely used coronary bypass conduit in addition to IMA in more than 90% of CABG worldwide\textsuperscript{[14]}. However, SV graft patency is inferior to IMA graft patency, with approximately 50% of SV grafts failing within 10 years and patients requiring regrafting to restore myocardial blood supply\textsuperscript{[15]}. As an in situ graft, IMA is relatively undamaged on exposure whereas, when harvested conventionally, SV is subjected to considerable vascular trauma. The conventional method of preparing SV for CABG in most cardiac centers is that originally described by Favaloro\textsuperscript{[15]}. When harvesting the SV in this way, considerable vascular damage is inflicted, particularly to the adventitia, and this affects graft quality and performance. In addition, a high proportion of SVs go into spasm at harvesting due to surgical trauma and direct handling of the vein by surgical instruments and this is overcome using intraluminal saline distension at pressures approaching 700 mmHg\textsuperscript{[17]}. These conditions cause damage to the endothelium (Figure 2) of both the SV lumen and vasa vasorum\textsuperscript{[18-24]}. This vascular damage may not only have an immediate effect on graft patency, for example, the vasospasm that occurs at harvesting and graft implantation, but may also stimulate processes influencing thrombotic occlusion, neointimal hyperplasia, and accelerated atherosclerosis, thus affecting both medium- and long-term graft performance.

Conventional SV grafts exhibit varying degrees of vascular damage that impact on graft patency whereas those harvested by the atrumatic, no-touch (NT) technique provide superior grafts that retain their normal architecture\textsuperscript{[25,26]}. Access to samples of both conventional and NT SV graft material offers the ability to

---

**Fig. 1** – Small bowel resection specimen from a coronavirus disease 2019 (COVID-19) patient stained with haematoxylin and eosin. Arrows point to dominant mononuclear cell infiltrates within the intima along the lumen of many vessels. The inset shows an immunohistochemical staining of caspase 3 (enzyme implicated in cell apoptosis) in small bowel specimens indicating apoptosis of endothelial cells and mononuclear cells (From Varga et al.\textsuperscript{[16]}, which is acknowledged).
Topal G, et al. - COVID-19, Endothelial Dysfunction and Saphenous Vein Graft Performance

Fig. 2 – Endothelium (En) of no-touch technique (A) and conventional technique (B) saphenous vein grafts for coronary artery bypass grafting. In A, note healthy intact En with the apical microvilli (asterisks). Bar: 10 μm. In B, note deformed En, endothelial lesions, and exposure of subendothelial connective tissue/matrix (asterisks). Bar: 20 μm. (From Vasilakis et al. [20], which is acknowledged).

Fig. 3 – A thinned cell of endothelium (En) containing mostly nucleus or ‘dense’ cytoplasm is protruding into the saphenous vein lumen (Lu). Arrow points to exposed subendothelial extracellular matrix (exm). sm=vascular smooth muscle; col=collagen. X 5,000. (From Ahmed et al. [19], which is acknowledged).

compare damaged (conventional) with normal, undamaged, SV (NT) used in patients undergoing CABG. Of particular relevance to the link between the endothelium and COVID-19 are the ultrastructural changes observed in conventional compared to samples of normal/NT SV. At the light microscope level, pronounced regions of endothelial denudation were identified in sections of conventional SV compared with normal/NT SV where the endothelium remains virtually intact [27]. Such endothelial damage exposes the intimal basement membrane (Figure 2B), providing potential sites for increased platelet aggregation, increased incidence of thrombotic occlusion, and graft failure [25]. Endothelial damage and/or dysfunction modifies the release and equilibrium between endothelium-derived substances such as nitric oxide (NO), prostanooids, and endothelin-1 (ET-1). In many situations, endothelial dysfunction leads to increased levels of ET-1 [28] and thromboxane [29], while there is a significant decrease in levels of NO and prostacyclin (PGI₂) [30-32]. Therefore, preventing or reducing endothelial damage in SV at harvesting would be expected to have a beneficial impact on graft patency. In addition, various in vitro experimental studies show that perivascular adipose tissue surrounding SV provides an additional source of PGI₂ and NO [31,34], potentially preventing platelet aggregation, thrombus formation, and vasospasm and thus confirming the beneficial effect of retaining SV perivascular adipose tissue on endothelial function when harvesting the SV for CABG [25].

At the ultrastructural level, Ahmed et al. [19] examined segments of SV harvested for CABG using conventional and NT techniques. The results showed better preservation of the ultrastructure of normal/NT SV grafts compared to those harvested conventionally. This included better preservation of the lumenal endothelium, endothelial cells of the vasa vasorum, and medial smooth muscle cells. The nuclei of endothelial cells of normal/NT SV protrude towards the lumen with junctions between the cells. Smooth muscle cells, elastin, and collagen fibers were also observed. At higher magnification, the nuclei, endoplasmic reticulum, Golgi apparatus, mitochondria, and Weibel-Palade bodies were evident [19]. There were dramatic morphological changes to a high proportion of endothelial cells in conventionally harvested SV (Figure 3). Polymorphism of the endothelium, cells with “dark” cytoplasm, or very thin cell processes protruding to the vein lumen were present. Some endothelial cells appeared “squashed” from the luminal side with others “thinned” and containing mostly nucleus or “dense” cytoplasm protruding into the SV lumen. Also, various squamous endothelial cell fragments were abundant in electron-transparent cytoplasmic vesicles and extracellular matrix.

Certain interesting features were also observed when comparing normal/NT and conventional SV vasa vasorum in
the tunica media. Vasa vasorum of normal/NT SV had typical-appearing endothelial cells surrounding an open lumen often containing characteristically shaped erythrocytes. By contrast, in conventional SV, clumps of erythrocytes were seen obstructing the lumen of the vasa vasorum. Interestingly, a similar situation has recently been observed in postmortem samples from patients with COVID-19 in China where “…prominent erythrocyte aggregates obstructing the lumen of capillaries… contribute to acute kidney injury, systemic hypoxia and abnormal coagulation…”[35].

Since it was reported that ACE2 is an active site of SARS-CoV-2 infections and is expressed in vascular endothelium, various comments have been raised regarding the involvement of endothelial dysfunction in the pathophysiology of cardiovascular complications induced by COVID-19 infection[4,10]. It has been suggested that increased risk of mortality in COVID-19 infected patients with diabetes, hypertension, and obesity might be related with the progression of endothelial dysfunction in these patients[10]. Early findings of Varga et al[4] on endothelial cell infection and endotheliitis in patients with COVID-19, suggest that vascular inflammation induces endothelial dysfunction that also causes increased vascular permeability and thrombin generation. Therefore, dysfunctional endothelium may become procoagulant. It has been demonstrated that increased levels of pro-inflammatory cytokines, including interleukin 1β, interleukin 6 (IL-6), and tumor necrosis factor alpha (TNFα), in patients with COVID-19 can induce upregulation of procoagulants[38]. Overall, SARS-CoV-2 binds ACE2 receptor on endothelial cells causing inflammatory cell infiltration, endothelial cell apoptosis, and vascular prothrombotic effects[4,10].

To date, there is no information regarding how COVID-19 affects coronary artery bypass graft vessels, in particular SV graft patency. In CABG patients, SARS-CoV-2 could bind ACE2 in SV and, therefore, influence the incidence of graft failure through an increase in vascular inflammation and vascular endothelial dysfunction. Moreover, the inflammatory effects of cytokines also result in activated vascular endothelial cells and endothelial injury with resultant prothrombotic properties[37]. Also, the increased release of pro-inflammatory cytokines, including TNFα and IL-6, from human SV under inflammatory conditions has been shown, suggesting the possible interaction of vascular inflammation, endothelial dysfunction, and the risk of thrombosis in SV graft failure[38]. Additionally, Chen et al[39] demonstrated that SARS-CoV-2 in the human heart attacks pericytes, causing capillary endothelial dysfunction, therefore favoring a microcirculation disorder. The authors suggest that these patients are more vulnerable to cardiac damage by COVID-19. Interestingly, the presence of pericytes on arteries and capillaries of human SV vasa vasorum system has been demonstrated using plasticized corrosion casts[40] (Figure 4). Based on these findings, we suggest that SARS-CoV-2 can invade pericytes of the adventitial vasa vasorum of SV leading to vascular dysfunction — e.g., by altering pericyte contractile properties[41], causing a reduction in diameter and blood flow of vasa microvessels, resulting in medial ischemia. Damage to vasa vasorum in vein grafts results in vessel wall hypoxia with subsequent neointima formation, similar to the observation described in arteries where occlusion of vasa vasorum leads to neointima formation and atherosclerosis[42-44]. In addition, the physiological properties of pericytes, including those of the vasa vasorum of human SV, are now recognized as cells involved in regenerative processes with a potential application for the treatment of CAD or other forms of heart damage[45-47]. Therefore, it seems desirable that SV used for myocardial revascularization in patients undergoing CABG should not be stripped of the adventitial vasa vasorum system and adjacent pericytes. Furthermore, Chen et al[39] described a pericyte/endothelium/COVID-19/ACE2 connection in cardiac injury, suggesting that “the endothelial cell of capillary and part of venules may play an essential role in myocardial microcirculation”. Thus, it might be suggested that a similar axis exists for the endothelium of both the lumen and vasa vasorum of the SV. On this basis, as in the human heart, “SARS-CoV-2 infection might attack pericytes and cause capillary/vasa vasorum endothelial cell dysfunction, thus inducing microcirculation disorder”. When using conventional SV harvesting are surgeons “using a damaged graft to repair a damaged heart” and what effect does damaging the endothelium have on CABG patients infected with COVID-19?

Overall, it is now suggested that vascular inflammation, endothelial dysfunction, and thrombosis might be some of the important key factors in the pathophysiology of COVID-19-induced cardiovascular effects. Therefore, immunomodulators like TNFα inhibitors in addition to anticoagulants and antiplatelet agents are recommended in the treatment of COVID-19[10]. Furthermore, a recent study demonstrated that RAAS inhibitors (ACE inhibitors and angiotensin-receptor blockers) do not have negative impact...
on patients with COVID-19. There are also recent observations and discussions regarding the imbalance in RAAS caused by COVID-19 that might be protected by the use of ACE inhibitors in COVID-19 patients.[48]. However, these findings and suggestions should be investigated in further clinical trials.

Varga et al.[5] suggest that ACE inhibitors and statins might have beneficial effects in preventing endothelial dysfunction in patients with COVID-19. This is a plausible hypothesis which suggests that therapeutic strategies focusing on endothelium-derived vasoactive factors may provide a timely opportunity for preventing or diminishing the development of endothelial dysfunction induced by COVID-19. In addition to ACE inhibitors and statins, ET-1 antagonists[56] and NO donors[55] might also be considered as compounds with the potential to improve SV graft performance in CABG patients infected by COVID-19. Antithrombotic strategies, including anticoagulants and antiplatelet agents in addition to RAAS inhibitors and immunomodulators, might also have beneficial effects on COVID-19-induced cardiovascular complications in CABG patients.

CONCLUSION

In this special article, we provide an overview regarding the possible effect of COVID-19 on patency rate of coronary artery bypass grafts, mainly with reference to the SV. We propose a therapeutic potential of focusing on endothelial dysfunction, vascular inflammation, and thrombosis, not just of ACE inhibitors but of other repurposed compounds that alone, or in combination with other drugs, might be used for protecting bypass grafts in COVID-19 infected CABG patients. Therefore, these drug therapies should be considered in future clinical and experimental studies focusing on COVID-19/endothelial and vascular functions in relation to patency rates of coronary artery bypass grafts.

No financial support.
No conflict of interest.

Authors’ roles & responsibilities

GT Substantial contributions to the conception or design of the work; drafting the work or revising it critically for important intellectual content; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published.

AL Substantial contributions to the conception or design of the work; drafting the work or revising it critically for important intellectual content; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published.

MRD Substantial contributions to the conception or design of the work; drafting the work or revising it critically for important intellectual content; agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved; final approval of the version to be published.

REFERENCES

1. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054-62. Erratum in: Lancet. 2020;395(10229):1083. Lancet. 2020;395(10229):1038. doi:10.1016/S0140-6736(20)30566-3.
2. Horton R. Offline: COVID-19 and the NHS-"a national scandal". Lancet. 2020;395(10229):1022. doi:10.1016/S0140-6736(20)30727-3.
3. Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular disease, drug therapy, and mortality in Covid-19. N Engl J Med. 2020;382(25):e102. Retraction in: N Engl J Med. 2020; doi:10.1056/NEJMoaa2007621.
4. Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, et al. Endothelial cell infection and endothelitis in COVID-19. Lancet. 2020;395(10234):1417-8. doi:10.1016/S0140-6736(20)30937-5.
5. Qanadli SD, Beigelman-Aubry C, Rottinger DC. Vascular changes detected with thoracic CT in coronavirus disease (COVID-19) might be significant determinants for accurate diagnosis and optimal patient management. AJR Am J Roentgenol. 2020;215(1):W15. doi:10.2214/AJR.20.23185.
6. Bai HX, Hsieh B, Xiong Z, Halsey K, Choi JW, Tran TML, et al. Performance of radiologists in differentiating COVID-19 from viral pneumonia on chest CT. Radiology. 2020;200823. doi:10.1148/radiol.2020200823.
7. ESC European Society of Cardiology: ESC Guidance for the Diagnosis and Management of CV Disease during the COVID-Pandemic [Internet]. France: ESC; 2020. [cited 2020 8 Jun]. p. 9-119. Available from: https://www.escardio.org/static_file/ESCardo/Education-General/Topic%20pages/Covid-19/ESC%20Guidance%20Document/ESC-Guidance-COVID-19-Pandemic.pdf
8. American College of Cardiology. ACC American College of Cardiology. COVID-19 clinical guidance for the cardiovascular care team [Internet]. Washington (DC): ACC; 2020. [cited 2020 8 Jun]. p. 1-4. Available from: https://www.acc.org/~/media/665FA1E710B8293138D4B8D1213.pdf
9. Li Y, Zhou W, Yang L, You R. Physiological and pathological regulation of ACE2, the SARS-CoV-2 receptor. Pharmacol Res. 2020;157:104833. doi:10.1016/j.phrs.2020.104833.
10. Henry BM, Vikse J, Benoit S, Favaloro EJ, Lippi G. Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: a novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis. Clin Chim Acta. 2020;507:167-73. doi:10.1016/j.cca.2020.04.027.
11. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res. 2000;87(5):E1-9. doi:10.1161/01.res.87.5.e1.
12. Borland JA, Chester AH, Morrison KA, Yacoub MH. Alternative pathways

761 Brazilian Journal of Cardiovascular Surgery
of angiotensin II production in the human saphenous vein. Br J Pharmacol. 1998;125(3):423-8. doi:10.1038/sj.bjp.0702018.

13. Zulli A, Burrell LM, Buxton BF, Hare DL. ACE2 and AT4R are present in diseased human blood vessels. Eur J Histochem. 2008;52(1):39-44. doi:10.4081/1184.

14. Schnwann TA, Habib RH, Wallace A, Shahian DM, O'Brien S, Jacobs JP, et al. Operative outcomes of multiple-arterial versus single-arterial coronary bypass grafting. Ann Thorac Surg. 2018;105(4):1109-19. doi:10.1016/j.athoracsur.2017.10.058.

15. Mehta D, Izzat MB, Bryan AJ, Angelini GD. Towards the prevention of vein graft failure. Int J Cardiol. 1997,62 Suppl 1:555-63. doi:10.1016/s0167-5273(97)00214-3.

16. Faveloro RG. Saphenous vein graft in the surgical treatment of coronary artery disease. Operative technique. J Thorac Cardiovasc Surg. 1969;58(2):178-85.

17. Bonchek LI. Prevention of endothelial damage during preparation of saphenous veins for bypass grafting. J Thorac Cardiovasc Surg. 1980;79(6):911-5.

18. Souza D. A new no-touch preparation technique. Technical notes. Scand J Cardiov. 1996;30(1):41-4. doi:10.3109/10471396901072399.

19. Ahmed SR, Johansson BL, Karlsson MG, Souza DS, Dashwood MR, Loesch A. Human saphenous vein and coronary bypass surgery: ultrastructural aspects of conventional and "no-touch" vein graft preparations. Histol Histopathol. 2004;19(2):421-33. doi:10.14670/HH-19.421.

20. Vasilakis V, Dashwood M, Souza DSR, Loesch A. Human saphenous vein and coronary bypass surgery: scanning electron microscopy of conventional and No-Touch vein grafts. Vasc Dis Prev. 2004;1(2):133-9. doi:10.2174/1567270043405204.

21. Dashwood MR, Anand R, Loesch A, Souza D. Hypothesis: a potential role for the vasa vasorum in the maintenance of vein graft patency. Angiology. 2004;55(4):385-95. doi:10.1177/0003319704055004005.

22. Dashwood MR, Anand R, Loesch A, Souza D. Hypothesis: a potential role for the vasa vasorum in the maintenance of vein graft patency. Angiology. 2004;55(4):385-95. doi:10.1177/0003319704055004005.

23. Dreifaldt M, Souza DS, Loesch A, Muddie JR, Karlsson MG, Filbey D, et al. The "no-touch" harvesting technique for vein grafts in coronary artery bypass surgery preserves an intact vasa vasorum. J Thorac Cardiovasc Surg. 2011;141(1):145-50. doi:10.1016/j.jtcvs.2010.02.005.

24. Verma S, Lovren F, Pan Y, Yanagawa B, Deb S, Karkhanis R, et al. Pedicled saphenous vein saphenous vein graft failure. Int J Cardiol. 1997;62 Suppl 1:S55-63. doi:10.1016/10.1152/j.athoracsur.2017.10.062.

25. Bonchek LI. Prevention of endothelial damage during preparation of saphenous veins for bypass grafting. J Thorac Cardiovasc Surg. 1980;79(6):911-5.

26. Souza D. A new no-touch preparation technique. Technical notes. Scand J Cardiov. 1996;30(1):41-4. doi:10.3109/10471396901072399.

27. Ahmed SR, Johansson BL, Karlsson MG, Souza DS, Dashwood MR, Loesch A. Human saphenous vein and coronary bypass surgery: ultrastructural aspects of conventional and "no-touch" vein graft preparations. Histol Histopathol. 2004;19(2):421-33. doi:10.14670/HH-19.421.

28. Vasilakis V, Dashwood M, Souza DSR, Loesch A. Human saphenous vein and coronary bypass surgery: scanning electron microscopy of conventional and No-Touch vein grafts. Vasc Dis Prev. 2004;1(2):133-9. doi:10.2174/1567270043405204.

29. Dashwood MR, Anand R, Loesch A, Souza D. Hypothesis: a potential role for the vasa vasorum in the maintenance of vein graft patency. Angiology. 2004;55(4):385-95. doi:10.1177/0003319704055004005.

30. Dashwood MR, Anand R, Loesch A, Souza D. Hypothesis: a potential role for the vasa vasorum in the maintenance of vein graft patency. Angiology. 2004;55(4):385-95. doi:10.1177/0003319704055004005.

31. Dreifaldt M, Souza DS, Loesch A, Muddie JR, Karlsson MG, Filbey D, et al. The "no-touch" harvesting technique for vein grafts in coronary artery bypass surgery preserves an intact vasa vasorum. J Thorac Cardiovasc Surg. 2011;141(1):145-50. doi:10.1016/j.jtcvs.2010.02.005.

32. Verma S, Lovren F, Pan Y, Yanagawa B, Deb S, Karkhanis R, et al. Pedicled saphenous vein saphenous vein graft failure. Int J Cardiol. 1997;62 Suppl 1:S55-63. doi:10.1016/10.1152/j.athoracsur.2017.10.062.

33. Bonchek LI. Prevention of endothelial damage during preparation of saphenous veins for bypass grafting. J Thorac Cardiovasc Surg. 1980;79(6):911-5.

34. Souza D. A new no-touch preparation technique. Technical notes. Scand J Cardiov. 1996;30(1):41-4. doi:10.3109/10471396901072399.

35. Ahmed SR, Johansson BL, Karlsson MG, Souza DS, Dashwood MR, Loesch A. Human saphenous vein and coronary bypass surgery: ultrastructural aspects of conventional and "no-touch" vein graft preparations. Histol Histopathol. 2004;19(2):421-33. doi:10.14670/HH-19.421.

36. Vasilakis V, Dashwood M, Souza DSR, Loesch A. Human saphenous vein and coronary bypass surgery: scanning electron microscopy of conventional and No-Touch vein grafts. Vasc Dis Prev. 2004;1(2):133-9. doi:10.2174/1567270043405204.

37. Dashwood MR, Anand R, Loesch A, Souza D. Hypothesis: a potential role for the vasa vasorum in the maintenance of vein graft patency. Angiology. 2004;55(4):385-95. doi:10.1177/0003319704055004005.

38. Dashwood MR, Anand R, Loesch A, Souza D. Hypothesis: a potential role for the vasa vasorum in the maintenance of vein graft patency. Angiology. 2004;55(4):385-95. doi:10.1177/0003319704055004005.

39. Dreifaldt M, Souza DS, Loesch A, Muddie JR, Karlsson MG, Filbey D, et al. The "no-touch" harvesting technique for vein grafts in coronary artery bypass surgery preserves an intact vasa vasorum. J Thorac Cardiovasc Surg. 2011;141(1):145-50. doi:10.1016/j.jtcvs.2010.02.005.

40. Verma S, Lovren F, Pan Y, Yanagawa B, Deb S, Karkhanis R, et al. Pedicled saphenous vein saphenous vein graft failure. Int J Cardiol. 1997;62 Suppl 1:S55-63. doi:10.1016/10.1152/j.athoracsur.2017.10.062.

41. Bonchek LI. Prevention of endothelial damage during preparation of saphenous veins for bypass grafting. J Thorac Cardiovasc Surg. 1980;79(6):911-5.

42. Souza D. A new no-touch preparation technique. Technical notes. Scand J Cardiov. 1996;30(1):41-4. doi:10.3109/10471396901072399.

43. Ahmed SR, Johansson BL, Karlsson MG, Souza DS, Dashwood MR, Loesch A. Human saphenous vein and coronary bypass surgery: ultrastructural aspects of conventional and "no-touch" vein graft preparations. Histol Histopathol. 2004;19(2):421-33. doi:10.14670/HH-19.421.

44. Vasilakis V, Dashwood M, Souza DSR, Loesch A. Human saphenous vein and coronary bypass surgery: scanning electron microscopy of conventional and No-Touch vein grafts. Vasc Dis Prev. 2004;1(2):133-9. doi:10.2174/1567270043405204.

45. Dashwood MR, Anand R, Loesch A, Souza D. Hypothesis: a potential role for the vasa vasorum in the maintenance of vein graft patency. Angiology. 2004;55(4):385-95. doi:10.1177/0003319704055004005.
47. Lametschwandtner A, Lametschwandtner U, Weiger T. Scanning electron microscopy of vascular corrosion casts—technique and applications: updated review. Scanning Microsc. 1990 Dec;4(4):889-940; discussion 941.

48. Cathery W, Faulkner A, Maselli D, Madeddu P. Concise review: the regenerative journey of pericytes toward clinical translation. Stem Cells. 2018;36(9):1295-1310. doi:10.1002/stem.2846.

49. de Abajo FJ, Rodríguez-Martín S, Lerma V, Mejía-Abril G, Aguilar M, García-Luque A, et al. Use of renin-angiotensin-aldosterone system inhibitors and risk of COVID-19 requiring admission to hospital: a case-population study. Lancet. 2020;395(10238):1705-14. doi:10.1016/S0140-6736(20)31030-8.

50. Dashwood M, Loesch A. Endothelin-1, endothelin receptor antagonists and vein graft occlusion in coronary artery bypass surgery: twenty years on and still no journey from bench to bedside. Can J Physiol Pharmacol. 2020. doi:10.1139/cjpp-2019-0598.

51. Zhang Y, Janssens SP, Wingler K, Schmidt HH, Moens AL. Modulating endothelial nitric oxide synthase: a new cardiovascular therapeutic strategy. Am J Physiol Heart Circ Physiol. 2011;301(3):H634-46. Erratum in: Am J Physiol Heart Circ Physiol. 2012;303(2):H241. doi:10.1152/ajpheart.01315.2010.

This is an open-access article distributed under the terms of the Creative Commons Attribution License.